Atsenatx
51 employees on LinkedIn · 3 known investors
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases. Its pipeline includes ATSN-201 for X-linked retinoschisis, ATSN-101 for LCA1, and earlier-stage programs for Usher Syndrome 1B and Stargardt disease.
Investors · 3
Frequently asked questions
- What does Atsenatx do?
- Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases. Its pipeline includes ATSN-201 for X-linked retinoschisis, ATSN-101 for LCA1, and earlier-stage programs for Usher Syndrome 1B and Stargardt disease.
- Who are Atsenatx's investors?
- Atsenatx's investors include Lightstone Ventures, Hatteras Venture Partners, Sofinnova Ventures.